生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

未开盘 05-27 16:00:00

5,152.456

-30.959

-0.60%

最高5,193.475	最低5,087.707	成交量2.39亿
今开5,181.657	昨收5,183.415	日振幅2.04%
总市值0.00	流通市值0.00	总股本0.00
成交额59.28亿	换手率--	流通股本0.00
市净率5.580127	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5152.456,"timestamp":1779869346412,"preClose":5183.415,"halted":0,"volume":238531983,"delay":0,"changeRate":-0.005973,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-30.958984,"latestTime":"05-27 16:00:00","open":5181.657,"high":5193.475,"low":5087.7065,"amount":5927723690,"amplitude":0.020405,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779931800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1779845400000,1779854400000],[1779858000000,1779868800000]],"pbRate":5.580127,"peRate":-422.06412,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2638234632","title":"瑞博生物-B(06938)提交RBD1119注射液用于治疗冠状动脉疾病的II期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2638234632","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638234632?lang=zh_cn&edition=full","pubTime":"2026-05-28 07:46","pubTimestamp":1779925602,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，已成功向欧洲药品管理局提交本公司自主研发产品RBD1119注射液用于治疗冠状动脉疾病的II期临床试验申请。尽管标准治疗已被广泛使用，但即使在最佳化治疗下，稳定型CAD患者仍面临发生血栓事件的较大残余风险。RBD1119注射液为一种新型抗血栓siRNA疗法，能提供有效及持久的血栓防护，同时保持良好的安全性特征，尤其是在出血风险方面。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B(06938)提交RBD1119注射液用于治疗冠状动脉疾病的II期临床试验申请","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638974689","title":"华昊中天医药-B(02563)：优替德隆4项临床研究成果入选2026年美国临床肿瘤学会(ASCO)年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2638974689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638974689?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:39","pubTimestamp":1779892799,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B 发布公告，公司核心产品优替德隆注射液及优替德隆胶囊的四项最新临床研究数据入选2026年美国临床肿瘤学会年会，进行壁报展示。本次入选的四项研究分别针对UTD2治疗晚期乳腺癌I/II期临床试验、UTD2治疗铂耐药卵巢癌II期临床试验、UTD1治疗HER2阳性晚期乳腺癌II期临床试验以及UTD1治疗去势抵抗性前列腺癌II期临床试验。2026 ASCO年会将于2026年5月29日至6月2日在美国芝加哥麦考密克会展中心举办。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02563","159938","BK1515","09939","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638081685","title":"亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买合共10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638081685","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638081685?lang=zh_cn&edition=full","pubTime":"2026-05-27 21:58","pubTimestamp":1779890296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月27日，受托人就2022年受限制股份单位计划目的于场内购买合共10万股现有股份以在归属后满足受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1161","BK4139","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638880146","title":"荃信生物-B(02509)就完成QX031N I期临床试验首例受试者给药收到罗氏支付的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2638880146","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638880146?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:58","pubTimestamp":1779886738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B 公布，公司已于2026年5月27日收到合作伙伴F.Hoffmann-LaRoche Ltd支付的里程碑付款，该付款乃基于QX031N项目完成I期临床试验首例受试者给药而触发。该研究于2026年3月27日完成首例受试者给药。于2025年10月28日，公司与罗氏达成全球独家合作与许可协议，授予罗氏开发、生产及商业化QX031N的全球独家权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140074392","title":"荃信生物获罗氏里程碑付款，首例受试者完成QX031n一期临床给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1140074392","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140074392?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:57","pubTimestamp":1779886637,"startTime":"0","endTime":"0","summary":"荃信生物-B宣布，因其与罗氏合作研发的药物QX031n一期临床试验首例受试者完成给药，公司已收到来自罗氏的里程碑付款。该款项的支付标志着双方合作项目取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638225688","title":"药捷安康-B(02617)完成发行合共383.6万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2638225688","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638225688?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:55","pubTimestamp":1779886557,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，配售协议所载所有条件均已达成，有关配售事项已于2026年5月27日完成。配售代理已成功以每股配售股份40.83港元的配售价向不少于六名承配人配售合共383.6万股配售股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638500140","title":"荃信生物-B(02509)5月27日斥资218.87万港元回购13.42万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638500140","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638500140?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:22","pubTimestamp":1779884579,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2026年5月27日该公司斥资218.87万港元回购13.42万股，回购价格为每股15.99-16.52港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638973502","title":"中慧生物-B(02627)委任雷美嘉为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2638973502","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638973502?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:31","pubTimestamp":1779881462,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B(02627)公布，雷美嘉女士已获选为第二届董事会独立非执行董事及董事会审计委员会成员，自2026年5月27日起生效。此外，柏淳已获委任为公司新任核数师，任期自2026年5月27日临时股东会结束起，直至公司下届股东周年大会结束为止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02627"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638020165","title":"康龙化成：拟投资30亿元建年产200吨医药中间体项目 分期至2030年完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2638020165","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638020165?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:31","pubTimestamp":1779881460,"startTime":"0","endTime":"0","summary":"5月27日，康龙化成（300759/03759）发布公告，公司计划通过全资子公司康龙化成（绍兴）新药生产有限公司，在绍兴市上虞区投资建设年产200吨医药中间体及API项目。项目的总投资金额为30亿元，旨在扩大高端医药中间体及原料药的产能规模，强化绿色制造技术的应用能力，并提升公司的CDMO服务能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605273751465310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1515","BK1161","159938","03759","BK1141","BK1576","09939","BK0216","300759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638150420","title":"贝莱德增持信达生物(01801)约36.95万股 每股作价约82.07港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638150420","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638150420?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:10","pubTimestamp":1779880225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月21日，贝莱德增持信达生物(01801)36.9453万股，每股作价82.0651港元，总金额约为3031.92万港元。增持后最新持股数目约为8728.09万股，最新持股比例为5.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1201861249.SGD","LU2430703095.HKD","BK4535","HK0000165453.HKD","LU0208291251.USD","LU0980610538.SGD","BK4135","LU0772969993.USD","BK4585","IE00B64PRP62.GBP","BK4567","BLK","IE00BGHQF631.EUR","BK4534","LU1509826696.USD","LU1989771016.USD","LU1291159041.SGD","LU1670627923.USD","LU2097828474.EUR","LU2097828557.USD","LU2328871848.SGD","EWH","BK4588","LU1280957306.USD","LU2505996509.AUD","BK1161","LU1599440770.SGD","IE00BVYPNV92.GBP","LU2097828714.EUR","IE00B3QW5Z07.USD","LU0640476718.USD","LU1481011911.USD","LU2242644610.SGD","IE00BDGV0183.EUR","BK4504","IE00B42XCP33.USD","LU1366333091.USD","LU1969619763.USD","LU2430703251.USD","LU0070302665.USD","01801","LU0742537680.HKD","LU1670628061.USD","LU1481011671.HKD","LU0320765489.SGD","LU2097828631.EUR","LU1074936037.SGD","BK1583","LU2430703178.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638501850","title":"亚盛医药-B(06855)：中英文简称将不再加上标记“B”","url":"https://stock-news.laohu8.com/highlight/detail?id=2638501850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638501850?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:31","pubTimestamp":1779877916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，由于相关规则不适用，公司的中英文简称自2026年6月1日起将不再加上标记“B”。公司的股份将以新英文股份简称“ASCENTAGE”及中文股份简称“亚盛医药”在联交所买卖。公司的股份代号维持不变，仍为“6855”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK4139","AAPG","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638508174","title":"18倍“奇迹”仅4个月便腰斩，北海康成-B(01228)陷入戴维斯双杀？","url":"https://stock-news.laohu8.com/highlight/detail?id=2638508174","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638508174?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:37","pubTimestamp":1779871059,"startTime":"0","endTime":"0","summary":"5月26日，北海康成-B股价大跌超10%，盘中最低价触及1.66港元，刷新年内新低，也让北海康成的股价回到去年8月12日公告宣布与百洋医药签订独家合作协议之前。2025年，港股医药板块涌现出一批“三倍股”、“四倍股”，但北海康成依旧能够凭借1824.81%的年度涨幅从其中脱颖而出。然而，反转发生在北海康成披露2025年报之后。根据北海康成在今年3月30日披露的2025年报，公司当期收入为4998.3万元，同比减少41.27%;净利润1481.8万元，同比扭亏为盈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"18倍“奇迹”仅4个月便腰斩，北海康成-B(01228)陷入戴维斯双杀？","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01228","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638570074","title":"诺诚健华(688428.SH)：奥布替尼获得澳大利亚药品管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2638570074","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638570074?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:27","pubTimestamp":1779870478,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 发布公告，近日，公司收到通知，奥布替尼已获澳大利亚药品管理局核准签发的上市许可。奥布替尼是公司自主研发的具有高度靶点选择性的新型BTK抑制剂，可有效规避脱靶效应引发的不良反应，显著提升治疗的安全性与有效性。在国际市场上，奥布替尼已在新加坡获批治疗r/rMCL和r/rMZL成年患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK0239","BK1574","688428","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638577682","title":"上海谊众(688091.SH)子公司在研创新药YXC-001临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2638577682","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638577682?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:39","pubTimestamp":1779867569,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海谊众 发布公告，公司全资子公司上海佑希创医药科技有限公司于近日收到国家药品监督管理局签发的《受理通知书》，公司自研创新药YXC-001用于晚期实体瘤治疗的临床试验申请已获正式受理。公告显示，针对现有单一靶点药物在疗效与毒性上难以平衡的痛点，公司基于独家的多功能抗体研发平台，前瞻性布局了全球领先的新一代抗肿瘤药物YXC-001。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","688091","BK1161","BK1574","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638729105","title":"港股异动 | 劲方医药-B(02595)尾盘涨超6% 两款在研新药的临床研究成果将登陆2026 ASCO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2638729105","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638729105?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:22","pubTimestamp":1779866560,"startTime":"0","endTime":"0","summary":"消息面上，劲方医药宣布，两款在研新药的临床研究成果将登陆2026 ASCO年会。此外，全球首款恶病质双抗GFS202A的临床数据也将首次在ASCO年会壁报环节展示。值得注意的是，5月25日，药物临床试验登记与信息公示平台官网显示，劲方医药登记了一项评估GFH375对比多西他赛治疗既往标准治疗失败的KRASG12D突变的局部晚期不可切除或转移性非小细胞肺癌试验参与者的随机对照、开放标签、多中心III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02595","VXUS","BK4588","BK1161","BK1515","09939","159938","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638574447","title":"众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2638574447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638574447?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:00","pubTimestamp":1779865244,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：已经26年5月底了，怎么还看不到昂拉地韦25年流感季的销量？是否在做数据？众生药业回复：您好！昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药，适用于成人单纯性甲型流感患者的治疗，销售与流感季节性相关。公司正持续推进学术推广与渠道建设，后续将结合流感周期与医保落地效应，稳步推动昂拉地韦片的商业化工作。谢谢！以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700024434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","BK1161","BK0077","06978","BK0188","002317","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638457426","title":"港股异动 | 映恩生物-B(09606)涨超5% 与BioNTech合作开发B7-H3 ADC全球Ⅲ期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2638457426","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638457426?lang=zh_cn&edition=full","pubTime":"2026-05-27 14:56","pubTimestamp":1779864979,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超5%，截至发稿，涨3.14%，报222.6港元，成交额1.52亿港元。消息面上，近日，据映恩生物-B官微消息，公司宣布，与BioNTech SE合作开发的靶向B7-H3的抗体偶联药物DB-1311/BNT324用于治疗未接受过紫杉烷类化疗的转移性去势抵抗性前列腺癌患者的全球Ⅲ期关键性注册临床研究已顺利完成全球首例患者入组给药。2026年5月12日，映恩生物行使独家选择权，参与分摊DB-1311/BNT324在美国地区的研发成本，并共享该药物商业化运营产生的盈亏收益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2543165471.USD","HK0000500386.USD","BK1161","BK4231","VXUS","BK4080","HK0000252152.HKD","09606","BK4588","ADC","BK4585","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638757191","title":"港股异动 | 剂泰科技-P(07666)盘中涨超11% 公司发布METiS AiProtein平台和抗体设计智能体AARON","url":"https://stock-news.laohu8.com/highlight/detail?id=2638757191","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638757191?lang=zh_cn&edition=full","pubTime":"2026-05-27 14:30","pubTimestamp":1779863423,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，剂泰科技-P盘中涨超11%，截至发稿，涨6.96%，报17.51港元，成交额6337.35万港元。消息面上，剂泰科技正式发布AiProtein平台以及抗体设计智能体AARON。作为剂泰科技AI纳米递送平台NanoForge驱动下的第四大核心解决方案，AiProtein与AiLNP、AiRNA和AiTEM共同完成了从蛋白设计、mRNA序列设计和LNP设计的剂泰科技“火箭+卫星”端到端研发闭环。剂泰科技将依托其全球首个AI纳米递送平台NanoForge，为沙砾生物解决新一代细胞治疗药物的递送瓶颈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","07666","BK4588","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638573568","title":"千红制药：公司创新药QHRD106项目正处于有序推进临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2638573568","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638573568?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:36","pubTimestamp":1779853004,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的创新药106是在什么时候获得CDE批准进行二期b补充验证临床试验的？千红制药回复：公司创新药QHRD106项目正处于有序推进临床试验阶段，相关进展请关注公司后续公告，感谢您的关注。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK1161","159992","06978","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638787565","title":"华东医药：自研创新药HDM1002、HDM1005、DR10624三款核心品种已推进至Ⅲ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2638787565","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638787565?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:33","pubTimestamp":1779852830,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药05月26日在投资者关系平台上答复投资者关心的问题。股票二级市场的波动受宏观经济、行业政策、市场情绪等多重因素影响。自研新药研发周期长、投入门槛高，具备客观行业规律。公司目前自研创新药HDM1002、HDM1005、DR10624 三款核心品种已推进至Ⅲ期临床。自今年年底开始，公司自研创新药将陆续递交上市申请。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","000963","LU1969619763.USD","BK0209","159992","BK1161","LU2328871848.SGD","BK0132","BK0187","BK0175","BK0183","BK0188","06978","BK0196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":-0.023},{"period":"3month","weight":-0.0399},{"period":"6month","weight":-0.0205},{"period":"1year","weight":0.0832},{"period":"ytd","weight":-0.0118}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}